(Stroke. 1997;28:2417-2420.)
© 1997 American Heart Association, Inc.
Articles |
A Mutation in Plasma Platelet-Activating Factor Acetylhydrolase (Val279
Phe) is a Genetic Risk Factor for Stroke
From the Department of Pathological Physiology (M.H., H.Y., T.I., K.S.), Institute of Neurological Diseases, Hirosaki University School of Medicine, Hirosaki, Japan, and the Department of Neurosurgery (N.Y.), the Yokohama General Hospital, Yokohama, Japan.
Correspondence to Kei Satoh, MD, Department of Pathological Physiology, Institute of Neurological Diseases, Hirosaki University School of Medicine, 5-Zaifucho, Hirosaki 036, Japan. E-mail pathophy{at}cc.hirosaki-u.ac.jp
Background and Purpose Platelet-activating factor (PAF)
is a phospholipid with multiple actions that include thrombosis and
inflammation. It is inactivated by a plasma enzyme, PAF
acetylhydrolase. Deficiency of this enzyme in plasma is caused by a
missense mutation in the gene (Val279Phe). We have
studied a possible association of this mutation with the risk of
stroke.
Subjects and Methods We studied 120 consecutive patients with cerebral thrombosis. The control group consisted of 134 patients matched for age and sex with minor complaints but without stroke. Genomic DNA was analyzed for the mutant allele by a specific polymerase-chain reaction. Plasma PAF acetylhydrolase activity was determined by the method of Stafforini et al.
Results The prevalence of the mutant gene was 43.4% in stroke
patients (39.2% heterozygotes and 4.2% homozygotes), which was
significantly higher than the 25.4% in control subjects (22.4%
heterozygotes and 3.0% homozygotes) (
2=9.22,
P<.01). The prevalence was slightly higher in stroke
patients without hypertension than those with hypertension, but the
difference was not significant. The patients with family histories of
stroke had a slightly higher but not a significant prevalence of the
mutant gene as compared with those without family histories of stroke.
Plasma PAF acetylhydrolase activity was higher in patients than in
control subjects, in normal subjects, or patients with a heterozygous
genotype.
Conclusions These results suggest that plasma PAF acetylhydrolase deficiency may be a risk factor for stroke. This may explain the relatively high prevalence of stroke in Japan, as the mutation is more common among Japanese than Caucasians.
Key Words: cerebral thrombosis • platelet-activating factor • mutation • risk factors
This article has been cited by other articles:
 |
|
 |
|
  N. Kono, T. Inoue, Y. Yoshida, H. Sato, T. Matsusue, H. Itabe, E. Niki, J. Aoki, and H. Arai Protection against Oxidative Stress-induced Hepatic Injury by Intracellular Type II Platelet-activating Factor Acetylhydrolase by Metabolism of Oxidized Phospholipids in Vivo J. Biol. Chem., January 18, 2008; 283(3): 1628 - 1636. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Jang, O. Y. Kim, S. J. Koh, J. S. Chae, Y. G. Ko, J. Y. Kim, H. Cho, T.-S. Jeong, W. S. Lee, J. M. Ordovas, et al. The Val279Phe Variant of the Lipoprotein-Associated Phospholipase A2 Gene Is Associated with Catalytic Activities and Cardiovascular Disease in Korean Men J. Clin. Endocrinol. Metab., September 1, 2006; 91(9): 3521 - 3527. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. L. Rufail, H. A. Schenkein, S. E. Barbour, J. G. Tew, and R. van Antwerpen Altered lipoprotein subclass distribution and PAF-AH activity in subjects with generalized aggressive periodontitis J. Lipid Res., December 1, 2005; 46(12): 2752 - 2760. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Zalewski and C. Macphee Role of Lipoprotein-Associated Phospholipase A2 in Atherosclerosis: Biology, Epidemiology, and Possible Therapeutic Target Arterioscler. Thromb. Vasc. Biol., May 1, 2005; 25(5): 923 - 931. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Campo, M. A. Sardo, A. Bitto, A. Bonaiuto, G. Trimarchi, M. Bonaiuto, M. Castaldo, C. Saitta, S. Cristadoro, and A. Saitta Platelet-Activating Factor Acetylhydrolase Is Not Associated with Carotid Intima-Media Thickness in Hypercholesterolemic Sicilian Individuals Clin. Chem., November 1, 2004; 50(11): 2077 - 2082. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Ninio, D. Tregouet, J.-L. Carrier, D. Stengel, C. Bickel, C. Perret, H. J. Rupprecht, F. Cambien, S. Blankenberg, and L. Tiret Platelet-activating factor-acetylhydrolase and PAF-receptor gene haplotypes in relation to future cardiovascular event in patients with coronary artery disease Hum. Mol. Genet., July 1, 2004; 13(13): 1341 - 1351. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. I. Kakafika, S. Xenofontos, V. Tsimihodimos, A. P. Tambaki, E. S. Lourida, R. Kalaitzidis, M. A. Cariolou, M. Elisaf, and A. D. Tselepis The PON1 M55L gene polymorphism is associated with reduced HDL-associated PAF-AH activity J. Lipid Res., October 1, 2003; 44(10): 1919 - 1926. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Lindsberg and A. J. Grau Inflammation and Infections as Risk Factors for Ischemic Stroke Stroke, October 1, 2003; 34(10): 2518 - 2532. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Prescott, T. M. McIntyre, G. A. Zimmerman, and D. M. Stafforini Sol Sherry Lecture in Thrombosis: Molecular Events in Acute Inflammation Arterioscler. Thromb. Vasc. Biol., May 1, 2002; 22(5): 727 - 733. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Ohshima, S. Ishii, T. Izumi, and T. Shimizu Receptor-dependent Metabolism of Platelet-activating Factor in Murine Macrophages J. Biol. Chem., March 15, 2002; 277(12): 9722 - 9727. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Bak, D. Gaist, S. H. Sindrup, A. Skytthe, and K. Christensen Genetic Liability in Stroke: A Long-Term Follow-Up Study of Danish Twins Stroke, March 1, 2002; 33(3): 769 - 774. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Fukunaga, S. Ishii, K. Asano, T. Yokomizo, T. Shiomi, T. Shimizu, and K. Yamaguchi Single Nucleotide Polymorphism of Human Platelet-activating Factor Receptor Impairs G-protein Activation J. Biol. Chem., November 9, 2001; 276(46): 43025 - 43030. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G.J. Hademenos, M.J. Alberts, I. Awad, M. Mayberg, T. Shephard, A. Jagoda, R.E. Latchaw, H.W. Todd, K. Viste, R. Starke, et al. Advances in the genetics of cerebrovascular disease and stroke Neurology, April 24, 2001; 56(8): 997 - 1008. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Hou, D. Osei-Hyiaman, H. Yu, Z. Ren, Z. Zhang, B. Wang, and S. Harada Association of a 27-bp repeat polymorphism in ecNOS gene with ischemic stroke in Chinese patients Neurology, February 27, 2001; 56(4): 490 - 496. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. M. McIntyre, G. A. Zimmerman, and S. M. Prescott Biologically Active Oxidized Phospholipids J. Biol. Chem., September 3, 1999; 274(36): 25189 - 25192. [Full Text] [PDF]
|
|
|
|
|
|
C. Lee, F. Sigari, T. Segrado, S. Horkko, S. Hama, P. V. Subbaiah, M. Miwa, M. Navab, J. L. Witztum, and P. D. Reaven All ApoB-Containing Lipoproteins Induce Monocyte Chemotaxis and Adhesion When Minimally Modified : Modulation of Lipoprotein Bioactivity by Platelet-Activating Factor Acetylhydrolase Arterioscler. Thromb. Vasc. Biol., June 1, 1999; 19(6): 1437 - 1446. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. SATOH, K. ASANO, K. NAOKI, K. FUKUNAGA, M. IWATA, M. KANAZAWA, and K. YAMAGUCHI Plasma Platelet-activating Factor Acetylhydrolase Deficiency in Japanese Patients with Asthma Am. J. Respir. Crit. Care Med., March 1, 1999; 159(3): 974 - 979. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. Ichihara, Y. Yamada, and M. Yokota Association of a G994->T Missense Mutation in the Plasma Platelet-Activating Factor Acetylhydrolase Gene With Genetic Susceptibility to Nonfamilial Dilated Cardiomyopathy in Japanese Circulation, November 3, 1998; 98(18): 1881 - 1885. [Abstract] [Full Text] [PDF]
|
|